Know Cancer

or
forgot password

Maintenance Therapy With Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia


Phase 2
18 Years
90 Years
Open (Enrolling)
Both
Chronic Lymphocytic Leukemia

Thank you

Trial Information

Maintenance Therapy With Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia


Inclusion Criteria:



- Previous induction treatment with bendamustine and rituximab

- 18 or more years of age

- chronic lymphocytic leukemia

- ECOG performance status less than or equal to 2

- Absolute neutrophile count more than 1,000

- Platelet count more than 70,000

Exclusion Criteria:

- Serious medical condition that would prevent treatment with lenalidomide

- Evidence of tumor lysis syndrome

- Any prior treatment with lenalidomide

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate

Outcome Description:

NCI sponsored Working Group Guidelines for CLL

Outcome Time Frame:

36 months

Safety Issue:

No

Principal Investigator

Terri L Parker, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Yale University

Authority:

United States: Institutional Review Board

Study ID:

1105008515

NCT ID:

NCT01465230

Start Date:

March 2012

Completion Date:

March 2016

Related Keywords:

  • Chronic Lymphocytic Leukemia
  • chronic lymphocytic leukemia
  • maintenance therapy
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid

Name

Location

Yale Cancer CenterNew Haven, Connecticut  06520-8028